Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Ford Employees Push to End Sales of Police Vehicles: Business Casual

Powered by RedCircle From a global pandemic to police brutality to an economic recession to systemic racism and more, our country is certainly experiencing an age of contention unlike any before—controversy that is bleeding through into our everyday lives and even drilling into the businesses we work for. Earlier this year, Amazon was beleaguered by…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share
Ford Employees Push to End Sales of Police Vehicles: Business Casual

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

Powered by RedCircle

From a global pandemic to police brutality to an economic recession to systemic racism and more, our country is certainly experiencing an age of contention unlike any before—controversy that is bleeding through into our everyday lives and even drilling into the businesses we work for.

Earlier this year, Amazon was beleaguered by petitions from their workers calling for the company to do more to keep them safe during the pandemic, while Google employees implored their leaders to stop working with U.S. border and immigration agencies, citing mistreatment of asylum seekers and refugees. And since George Floyd’s brutal death while in police custody back in May, protests, demonstrations and general outrage have resulted in the Black Lives Matter movement calling for police defunding, an effort aimed at changing the role of law enforcement in communities across America. This effort is being echoed throughout the halls of the Ford Motor Company as well, with approximately 100 employees asking the auto giant in a letter to stop the production and selling of police vehicles.

On this snippet of Business Casual, co-hosts Daniel Litwin and Tyler Kern break down:

  1. The employees and groups who authored and/or are behind the letter sent to Ford management
  2. The highlights of CEO Jim Hackett’s response to salaried worker
  3. The number of law enforcement vehicles Ford produces, their share in the company’s overall sales revenues, and the role these cars play in vehicle technology testing
  4. Ford’s 70-year history as a major provider of police packages
  5. The trend in employee protests that are forcing major multinational corporations to rethink relationships with polemical institutions

Bringing thought leadership to your day, MarketScale’s Business Casual keeps you current with the hottest topics, latest events and newest trends shaping business today. And to stay on the cutting edge of the most recent news and event coverage across B2B, be sure to check out our industry pages.

Be sure to subscribe to our industry publication for the latest news, videos, and podcasts in the Transportation Industry.

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly has broken ground on a $6.5 billion manufacturing facility in Houston, slated for completion around 2030. While attention has focused on scaling production of Foundayo, its oral GLP-1 treatment, the project also reflects broader U.S. efforts to rebuild domestic pharmaceutical manufacturing and highlights the supply chain challenge of forecasting demand and building capacity years in advance.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain, making it difficult to commit billions to manufacturing capacity years before demand and required output are clear.
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

NextGen Invent’s Deepak Mittal argues for scoped healthcare AI pilots with early governance

NextGen Invent’s Deepak Mittal argues that healthcare AI pilots can begin with a reliable data subset and early governance. His performance figures are vendor claims, not independently verified results.

  • 01Deepak Mittal advocates starting with a defined problem and suitable data rather than waiting for perfect organization-wide data.
  • 02Some performance figures cited in the interview (for example, preparation time and model counts) are company-reported and not independently verified in this article.
  • 03NIST’s voluntary AI Risk Management Framework provides an independent structure for governance and risk evaluation.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512